NCT03950336Befejeződött
Prebiotics and Diet to Reduce "Leaky" Gut in First Degree Relatives of Crohn's Disease Patients
Influence of Prebiotics on Intestinal Permeability in First Degree Relatives of Crohn's Patients
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2024. máj. 20.
Rövid összefoglaló (regiszter, angolul)
Crohn's disease (CD) is a recurring inflammation of the intestines. The etiology is unknown; however evidence suggests that it could be a combination of gut microbes, environmental factors and genetics. CD has a strong genetic component, with up to 12% of patients having familial history. The Western diet is also thought to increase the risk of developing CD. In addition up to 20% of healthy first-degree relatives (FRD) of CD patients have increased small intestinal permeability ("leaky gut"). Previous studies have also shown that the Western diet can affect the intestinal immune response and normal intestinal barrier function, as well as alter the gut microbiota. We are interested in looking into whether beneficial dietary fibers (prebiotics) in combination with a diet low in n-6 polyunsaturated fatty acids (PUFAs) and high in n-3 PUFAs can protect against the development of CD. Prebiotics are carbohydrates that cannot be digested by human enzymes and instead feed the bacteria in the colon that can digest them. Prebiotics occur in different fruits and vegetables. They have been shown to improve health by positively changing the gut microbes and their metabolism. The prebiotic we will be using are β-fructans. β-fructans have been shown to reduce "leaky gut" and positively impact the intestinal immune system in experimental models and healthy humans. Diet has been shown to affect the gut microbes, intestinal inflammation development and the activity of prebiotics. We hypothesize that β-fructans in combination with a diet low in n-6 PUFAs / high in n-3 PUFAs (similar to a Mediterranean diet) can reduce intestinal permeability ("leaky gut") in FDR of CD patients, associated with beneficial changes in the gut microbes. Participants (FDR of CD patients; 40 total) will be randomized and receive either a 12 g/day dose of the prebiotic oligofructose-enriched inulin (Prebiotin), or placebo (maltodextrin), as well as a dietary intervention. In order to control the n-3 and n-6 PUFA intake, participants will receive nutritional counselling by a registered dietitian. The Mediterranean diet will have the low n-6 and high n-3 intake ("Low n-6 PUFA"). Participants in the control diet group will be advised to follow the Canada's Food Guide (CFG) recommendations. Thus, this placebo-controlled study will involve 2 intervention groups with 20 participants in each group: 1) Prebiotic + Low n-6 PUFA; 2) Placebo + CFG.
- Állapot (regiszter)
- Befejeződött
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 33 (tényleges)
- Első benyújtás
- 2019. máj. 13.
- Kezdés
- 2020. febr. 4.
- Elsődleges befejezés
- 2024. jan. 8.
- Fő szponzor
- University of Alberta
- Betegségek
- Crohn-betegség
- NCT-szám
- NCT03950336
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Bevont résztvevők: 33
- 2020. febr. 4. és az elsődleges befejezés (2024. jan. 8.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Alcohol or drug abuse;
Más betegség
- Celiac disease (allergic reaction to wheat products), gluten intolerance/sensitivity;
- Having history or evidence of significant gastrointestinal dysfunction and Irritable Bowel Syndrome (IBS);
- Having an active gastrointestinal infection (confirmed by stool pathogen culture test and Clostridioides difficile test)
- Having history or evidence of blood and bleeding disorder;
- Having a significant chronic disorder such as immune disorders, organ transplant, severe cardiac disease, renal failure, severe pulmonary disease, severe psychiatric disorder;
Laborértékek
- Diabetes or uncontrolled / unstable blood glucose levels;
Egyéb
- Use of probiotic and prebiotic supplements, fish oil or NSAIDS, prescribed or over the counter in the last 1 week;
- Use of antibiotics in the last 2 months;
- Having uncontrolled or unstable blood pressure;
- Pregnant or lactating;
- Not able to consent to the study.
Kiket keres a vizsgálat
- Males and females aged 15 - 50;
- First degree relative (parent, sibling, child) of patient diagnosed with Crohn's disease;
- Agree not to use any dietary supplements, herbal treatments, probiotics, prebiotics or dietary therapies within 1 week of starting the trial and during the study;
- Willingness to keep current physical activity during study period;
- Ability to give valid informed consent
- For females of childbearing potential and sexually active, a negative pregnancy test at screening, baseline and end-of-study, and accord to use appropriate birth control method (hormonal contraceptives, intrauterine devices, vasectomy/tubal ligation, barrier methods (condom or diaphragm), double-barrier methods or abstinence) during study period.
Életkor a regiszterben: 15 év – 50 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| University of Alberta | Edmonton | Kanada | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.